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Introduction: The 5-HTT short allele has been controversially associated with an increased risk of 
major depressive disorder.
Objective: To determine the association of 5-HTT short allele with major depression in Bogotá, Colombia.
Materials and methods: We carried out a study of cases (n=68) matched 1:1 with controls by gender 
and age (±5 years). Major depression was diagnosed using the Mini-International Neuropsychiatric 
Interview, and 5-HTT polymorphism using PCR.
Results: Females were predominant (82.4%). The S (short) allele predominated in cases compared 
with controls (S: 72.1% vs. 63.2; L (long): 27.9% vs. 36.8%), and the SL genotype was more frequent 
in cases (SL: 45.6% vs. 36.8%; LL: 27.9% vs. 36.8%; SS: 26.5% vs. 26.5%), although not significantly. 
There were significant differences in those under age 37, with a predominance of the S allele in cases 
(p=0.038; OR=2.75; 95% CI: 0.88-8.64). Multivariate analysis, adjusted for comorbid anxiety disorders, 
showed a significant association of major depression with the SL genotype (p=0.049; OR=3.20; 95% 
CI: 1.00-10.23); the S allele was close to statistical significance (p=0.063; OR=2.94; 95% CI: 0.94-
9.13), and it was statistically significant in cases under 37 years of age (p=0.026; OR=10.79; 95% CI: 
1.32-80.36).
Conclusions: The SL genotype was associated with major depressive disorder in patients of all ages. 
The S allele was significantly associated with major depressive disorder in patients under age 37, 
adjusted for comorbid anxiety disorders.
Key words: serotonin; polymorphism, genetic; depressive disorder, major; anxiety disorders; suicide; 
risk; comorbidity.
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Polimorfismo del gen del transportador de serotonina (5-HTT) y trastorno de depresión mayor 
en pacientes en Bogotá, Colombia
Introducción. El polimorfismo 5-HTT se ha asociado con el trastorno de depresión mayor, aunque el 
planteamiento ha generado controversia.
Objetivo. Determinar la asociación del polimorfismo 5-HTT con la depresión mayor en Bogotá, Colombia.
Materiales y métodos. Se hizo un estudio de casos y controles pareado por sexo y edad (±5 años), 
con una razón de uno a uno (68:68). El trastorno de depresión mayor se diagnosticó con el cuestionario 
Mini-International Neuropsychiatric Interview, y, el polimorfismo 5-HTT, mediante reacción en cadena 
de la polimerasa (PCR). 
Resultados. Las mujeres predominaron entre los participantes (82,4 %). El alelo corto (short, S) 
predominó en los casos comparados con los controles (S: 72,1 % Vs. 63,2; L (long): 27,9 % Vs. 
36,8 %), y el genotipo SL fue más frecuente en los casos (SL: 45,6 % Vs. 36,8 %; LL: 27,9 % Vs. 
36,8 %; SS: 26,5 % Vs. 26,5 %), aunque no significativamente. Hubo diferencias significativas en 
menores de 37 años, con predominio del alelo S en los casos (p=0,0384; odds ratio - OR=2,75; IC95%: 
0,88-8,64). El análisis multivariado ajustado por trastornos concomitantes de ansiedad mostró una 
asociación significativa de la depresión mayor con el genotipo SL (p=0,049; OR=3,20; IC95% 1,003-
10,233); el alelo S estuvo cerca de la significación estadística (p=0,063; OR=2,94; IC95% 0,94-9,13), 
y fue estadísticamente significativo en los casos de menores de 37 años (p=0,026; OR=10,79; IC95% 
1,32-80,36).
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Conclusiones. El genotipo SL se asoció con el trastorno de depresión mayor en pacientes de todas 
las edades. El alelo S se asoció significativamente con el trastorno de depresión mayor en pacientes 
menores de 37 años al ajustar por trastornos concomitantes de ansiedad.
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The major depressive disorder is a globally signi-
ficant public health problem. It is highly prevalent, 
chronic and incapacitating, it occurs frequently with 
comorbidities, and results in loss of productivity, 
increased mortality rates, and, additionally, its 
medical treatment is very expensive for countries.
Lifetime prevalence of major depression episodes 
in the general population varies considerably 
among countries, although in most it is 8-12%; in 
some, like Japan, it is 3%, and in others, like the 
United States, it is 16.9% (1). In Colombia, the last 
National Mental Health Survey conducted in 2003 
showed a lifetime prevalence of mood disorders 
of 15.0%, with major depressive disorder being the 
most frequent (12.1%) (2). 
According to the World Health Organization (WHO), 
the major depressive disorder is one of the most 
common causes of disability and burden of disease 
worldwide (3,4); it is projected that it will be in the 
second place in 2020, and in the first place in 
2030 (4). The major depressive disorder is one of 
the five main factors associated with absenteeism 
and decreased work capacity (5). Added to the 
medical treatment costs are those caused by the 
loss of productive capacity and decreased work 
performance (6).
In Colombia, the major depressive disorder is 
the first cause of disease burden in women, and 
the second in men, after cardiovascular diseases, 
especially in the most productive ages (7).
The major depressive disorder is a complex, multi-
factorial disease, with very heterogeneous clinical 
manifestations, whose etiological and pathological 
mechanisms have not been completely elucidated. 
It is considered inheritable, of polygenic origin, 
with clinical manifestations resulting from genetic-
environmental interactions (8). The hereditability 
of the major depressive disorder has been esti-
mated at 37%, with a range of 31-42% (9). The 
characteristics of the familial pattern include early 
appearance of symptoms, chronic course, and 
frequent recurrences (10). Having a first-degree 
relative with major depressive disorder increases 
the risk of developing it by two to three times, 
compared with the risk of the general population 
(11). In addition, some authors have proposed 
a greater hereditability of the major depressive 
disorder in women than in men (12).
One of the most noted factors in the biological 
etiology and pathological pathways of the major 
depressive disorder has been the serotonin 
transporter, 5-HTT (SERT); many current anti-
depressant medications exert their effect here. 
The transporter regulates the concentration of 
serotonin in the synaptic space, being essential 
for mood regulation (13).
The gene that codes the serotonin transporter 
protein in the presynaptic neurons is located on 
the long arm of human chromosome 17 (17q11-
12). The insertion/deletion (in/del) polymorphism 
of 44 bp in the transcription control region has 
been one of the most studied in the 5-HTT gene. 
This polymorphism results in two allele variations 
with different sizes and activity: A long allele 
(L) with 16 repetitions, and a short one (S), with 
14. Each individual may be a carrier of one of 
the two homozygotic combinations, LL, SS, or a 
heterozygotic combination, SL. In human cells, 
the S allele reduces the activity of the transporter, 
which decreases the levels of messenger RNA 
and the expression of presynaptic 5-HTT (14-16). 
It has been found that the LL cells can produce 
messenger RNA levels for 5-HTT 1.4 to 1.7 times 
greater than those of the short allele (14). In turn, 
the LL variant of 5-HTT is capable of removing 
1.9 to 2.2 times more serotonin from the synaptic 
cleft than the SS or SL variants (17). The short 
allele of this polymorphism produces lower levels 
of transporter transcription, which has associated 
it with a greater risk of bipolar and unipolar mood 
disorders (18,19).
287
Biomédica 2016;36:285-94 5-HTT gene polymorphism and major depressive disorder
The association of this mutation with major 
depressive disorder has been one of the most 
researched, reporting a statistically significant 
association. Haenisch, et al., found a significant 
association between the short (S) allele and 
major depressive disorder (19). However, the 
results have been controversial, since they have 
not coincided among researchers. Some authors 
have found this statistical association between the 
5-HTT (in/del O indel) polymorphism and mood 
disorders, particularly major depression, shown 
additionally in meta-analyses such as that of 
López-León (19-21). Anguelova, et al., also found 
a strong association between the 5HTT gene 
in/del polymorphism and the risk of suicide (22), 
and other authors demonstrated the association 
between this polymorphism and bipolar affective 
disorder (20,23). However, in Western European 
descendants, Hoehe, et al., found no significant 
differences in the genotypic or allele frequencies 
of the 5-HTT polymorphism in 36 patients with 
major depression, 79 with bipolar I disorder, and 
294 controls (24). In Germany, Minov, et al., found 
a greater proportion of SS homozygotes in 173 
cases of major depression (23.1%) compared with 
121 controls (14.0%), although the difference was 
not statistically significant (25). Medlewicz, et al., 
in a large, multi-centric study in Europe, found no 
significant differences in 539 cases of major unipolar 
depression and 821 controls regarding the effect 
of this polymorphism on the susceptibility to major 
depression; in this study, the authors discarded the 
possibility of negative results being attributable to a 
lack of statistical power (26). Serretti, in turn, did not 
find an association between 5HTT polymorphism 
and severe psychotic disorders in Italy (27).
Three studies have been published in Colombia 
on the association of 5-HTT polymorphism with 
mood disorders. Two of them have involved bipolar 
disorder cases (BPD I): one in Medellín with 
participants from all the department of Antioquia 
(28), and the other, in the Colombian coffee-
growing region (departments of Risaralda and 
Quindío) (29).
Only one of the Colombian studies involved 
major depressive disorder cases (30). These three 
studies found no statistically significant association 
between 5-HTT polymorphism and the evaluated 
mood disorder. However, this last study on major 
depressive disorder showed that the absence of 
the S allele conferred a protective tendency against 
the major depressive disorder, although it did not 
achieve statistical significance. 
The present study evaluated the association 
between the in/del polymorphism of the serotonin 
transporter gene (5-HTT) and major depressive 
disorder in a group of Colombian patients residing 
in Bogotá, Colombia. 
Materials and methods
This was a case-control study paired by sex and 
age (± 5 years).
Recruitment process
Cases and controls were recruited between 
September, 2011, and July, 2013, in outpatient 
departments and hospitalization services in private 
psychiatric institutions and public hospitals in 
Bogotá, especially in those where Universidad del 
Rosario’s psychiatry residents and collaborating 
psychiatrists carried out their practice. Patients and 
controls assessed with the Mini-International Neuro-
psychiatric Interview (MINI), were screened for major 
depressive disorder and other axis I disorders.
Selection criteria
The inclusion of participants was based on the 
fulfillment of the diagnostic criteria for major 
depressive disorder established in the American 
Psychiatric Association’s Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV-TR). The 
potential cases were patients diagnosed as major 
depressive disorder cases in the psychiatric serv-
ices in Bogotá. Exclusion criteria for cases included 
those patients who had a major depressive episode 
in the context of a bipolar mood disorder, mental 
retardation, or pervasive developmental disorder; 
patients with psychotic symptoms characteristic of 
schizophrenia or other psychoses, or those who did 
not want to participate in the study. After evaluating 
the inclusion and exclusion criteria, and signing 
the informed consent, 87 cases that fulfilled the 
selection criteria were initially pre-selected.
We selected the controls from hospital and university 
academic and administrative personnel after invit-
ing adult volunteers from all departments of the 
institutions collaborating in the study to participate. 
An individual appointment was set up to evaluate the 
inclusion and exclusion criteria and for participants to 
sign the informed consent, until the required number 
of controls was recruited among those who did not 
fulfill the diagnostic criteria for major depressive 
disorder using the structured MINI interview.
The exclusion criteria for controls were the following: 
those who had a bipolar affective disorder, potential 
controls with a family history of major depressive 
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disorder, or controls using illegal psychoactive 
substances, due to the known association between 
these disorders and mood disorders. We selected 
131 controls from the above-mentioned institutions. 
Participants were between 18 and 79 years old, 
residing in Bogotá, who agreed to participate in the 
study by signing the informed consent.
Data collection and study variables
The data collection instrument included demo-
graphic variables (age, educational level, gender, 
marital status, socioeconomic status), as well 
as the body mass index (BMI), co-morbidities, 
use of psychoactive substances, smoking and/or 
alcohol consumption, other axis I diagnoses from 
the DSM-IV-TR, prior hospitalizations in mental 
health units, prior treatment with anti-depressants, 
family history of mental illness, characteristics of 
the major depressive illness (relapses, presence 
of melancholic symptoms), suicidal behavior, 
and the results on the presence of 5-HTT gene 
polymorphism.
Genetic analysis
Blood samples were taken for genotyping. For both 
cases and controls, subjects on whom genotyping 
could not be performed were excluded. After 
applying the inclusion and exclusion criteria, and 
the pairing techniques according to sex and age 
variables to pre-selected cases and controls, the 
final group included 136 participants, 68 cases and 
68 controls, paired by sex and age (± 5 years). 
Genetic analysis was performed in the Genetics 
Department of the Universidad del Rosario as 
described below. The peripheral blood samples 
underwent DNA extraction using conventional 
salting out techniques. A polymerase chain reaction 
(PCR) was performed with specific primers designed 
for analyzing 5-HTT polymorphism. All the amplified 
products were analyzed in agarose gels stained 
with 1.2% ethidium bromide. For each PCR run, a 
negative control was used, which established the 
absence of contamination. Genotypification was 
performed by two geneticists from the Universidad 
del Rosario Genetics Department, with inde-
pendent evaluations. No analytical discrepancies or 
Mendelian errors were seen. The analyzed alleles 
pertained to insertion (419 bp) or deletion (375 bp) 
of 44 bp.
Statistical analysis 
The information obtained from the cases and 
controls was transcribed to a data base (Microsoft 
Office Excel, version 2010). In order to guarantee 
the quality of the information and avoid classification 
biases, data base cleansing was performed with 
verification by two observers. Finally, transcription 
errors were evaluated with simple frequencies and 
logical cross-checks between variables. Processing 
was done on Epi-Info, version 7.0; STATA® 11.0, 
and SPSS®, version 20.0.
We described independent variables and evaluated 
the normality of the quantitative variables using 
the Shapiro-Wilk test with a 10% significance level 
(p<0.10). For continuous and discrete quantitative 
variables with an approximately normal distribution, 
the arithmetic mean was used as the measure of 
central tendency, and standard deviation as the 
measure of dispersion. For quantitative variables 
with a non-normal distribution, we used the median 
and the range. Categorical variables were displayed 
in tables with absolute and relative frequencies 
expressed in percentages.
In the bivariate analysis, we evaluated the probability 
of the presence of associated qualitative factors 
with a dichotomous variable (exposure) and major 
depression. We used 2 x 2 tables to obtain the 
odds ratio (OR) and its respective 95% confidence 
interval, with estimations of paired maximum-
likelihood, McNemar´s chi squared test for asymptotic 
association, and the Mantel-Haenszel test without 
correction and with continuity correction (expected 
values ≥5), or Fisher´s exact test, or the mid-p test, 
for related samples (expected values <5). 
In factors associated with a multinomial variable, 
we used the conditional logistic regression for 
paired cases and controls with a 1:1 ratio through 
contrasts for indicator variables, taking one of the 
k categories as a base and creating k-l indicator 
variables. Factors with a quantitative variable were 
also evaluated using conditional logistic regression. 
The interaction or modification of the factors´ effects 
was evaluated in the conditional logistic regression 
model. Previously, we evaluated the assumption of 
multi-colinearity between the independent variables. 
We evaluated the association between 5-HTT 
gene polymorphism and major depressive disorder 
adjusting for confounding variables, and using the 
conditional logistic regression model, as well as 
the presence of Hardy-Weinberg equilibrium by 
Pearson´s chi- squared test. The level of signifi-
cance used in the bivariate and multivariate analysis 
was 5% (p<0.05).
We performed a post hoc power analysis. Exploring 
the association of the 5-HTT polymorphism and 
major depression disorder in a multivariate analysis 
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of 68 matched cases and controls of all ages, the 
SL genotype was present in 36.8% of controls and 
in 45.6 % of cases, yielding an OR of 3.2 with a 
95% confidence level (p=0.049) and a statistical 
power of 90.6%. 
We analyzed the association of the 5-HTT poly-
morphism and major depression disorder in 35 
matched young cases (36 years old or younger), 
and found that the S allele was present in 51.5% 
of controls and in 74% of cases, yielding an OR 
of 2.75 with a 95% confidence level; however, the 
statistical power was 49.1%, probably because the 
younger cases were a small sample of 35 cases 
and 33 controls. 
The project was approved by the Research Ethics 
Committee of the Universidad del Rosario, and 
classified as a minimal risk study, since a blood 
sample no greater than 10 ml was taken from 
participants. All patients and controls signed an 
informed consent for the use of their DNA samples. 
The project adhered to the national ethical norms 
as stated in Resolution 8430 of 1993, and the 
international ethical norms for human research.
Results
The study group included 136 individuals: 68 cases 
and 68 controls. According to the results of the struc-
tured DSM-IV-TR MINI interview, the cases fulfilled 
the criteria for major depressive disorder; 70.6% 
of these patients had melancholic symptoms, and 
64.2% had some degree of suicide risk; the suicide 
risk was classified as slight (32.8%), severe (25.4%), 
and moderate (6.0%); 47.1% (n=32) of participants 
had received prior antidepressant therapy, and 
19.1% of them (n=13), more than one treatment. 
The most prescribed medications were fluoxetine 
(40%), sertraline (24%) and amitriptyline (9%).
In the general group there was a 4.7:1 female-male 
ratio, a mean age of 37.7 ± 11.1 O 37.7±11.1years 
and a median of 36 years that was used as a cut-
off point for exploring the association of the 5-HTT 
gene polymorphism and the major depressive 
disorder risk. Although most participants were 
single (42.8%), 43.4% reported having a stable 
partner; 25.7% of participants had professional 
training; 20.6% had completed graduate studies, 
and 1.5% had not attended school. As for their 
socio-economic status, most participants belonged 
to middle levels:  39.7% to level 3 (out of 6) and 
25.7% to level 2 (out of 6). There were no signifi-
cant differences in demographic variables between 
cases and controls (table 1).
Clinical characteristics and history
The average body mass index (BMI) of cases 
was 24.7 ± 4.8 O 24.7±4.8kg/m2 (med=24), and 
of controls, 23.9 ± 3.1 kg/m2 (med=24), without 
significant differences (p=0.576, Wilcoxon´s test). 
The prevalence of current smoking was significantly 
greater in cases than in controls (23.5% vs. 2.9%; 
p=0.0003; OR=15; 95% CI: 1.98-113.56); there 
was no association between alcohol use and major 
depression. In the evaluation of family and personal 
history there was a greater frequency of prior depres-
sion and antidepressant therapy in cases than in 
controls (p<0.001, McNemar´s test) (table 2).
Psychiatric comorbidities
The comorbidities found to be significantly associ-
ated with major depressive disorder among cases 
were anxiety disorder sometime in their lifetime, 
and generalized anxiety disorder; the other comor-
bidities did not show a significant association. The 
severity of suicide risk was greater in cases than 
in controls (slight: 32.8% vs. 4.4 %, moderate: 
6.0% vs. 0%, and severe: 25.4% vs. 0%) (p<0.001; 
OR=42.0; 95% CI: 5.78-305.16) (table 3).
Table 4 shows the distribution of the genotype 
and allele frequencies of the 5-HTT gene in the 
study sample. The study population was in Hardy-
Table 1. Socio-demographic variables, 5-HTT polymorphism, 
and major depressive disorder. Paired case-control study. 
Bogotá, Colombia, 2013.
Variable Cases Controls  p
n % n %
Age group (years)
≤36 35 51.5 33 48.5 0.732
≥37 33 48.5 35 51.5
Total 68 100 68 100
Sex
Women 56 82.4 56 82.4 1.000
Men 12 17.6 12 17.6
Total 68 100 68 100
Marital status
Married or stable partner 39 57.4 39 57.4 1.000
Single or separated 29 42.6 29 42.6
Total 68 100 68 100
Economic status 
Low (1 & 2) 20 29.4 16 23.5 0.690
Middle (3 & 4) 41 60.3 43 63.2
High (5 & 6)   7 10.3   9 13.2
Total 68 100 68 100
Educational level
High 30 44.1 33 48.5 0.112
Middle 22 32.4 28 41.2
Low 16 23.5   7 10.3
Total 68 100 68 100
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Weinberg equilibrium (p>0.05). The SL genotype 
and S allele group frequency was greater in cases 
than in controls, although with no significant 
difference; the frequency of the S allele was 
significantly greater in the group of cases under 
the age of 37. 
Multivariate analysis
In the conditional logistic regression model, the 
SL heterozygote of the 5-HTT gene polymorphism 
was found to be significantly associated with 
major depression after adjusting for co-morbid 
anxiety disorders (generalized anxiety and anxiety 
disorder at least once in their lifetime). The 
severity of the suicide risk was found to be very 
significantly associated with major depression, and 
was ultimately excluded from the model due to its 
high colinearity with generalized anxiety disorder 
(p=0.018; OR=5.15; 95% CI: 1.26-20.96) and with 
anxiety disorder at least once in their lifetime 
(p=0.003; OR=3.89; 95% CI: 1.53-9.88).
In the conditional logistic regression model, the 
S allele was found to be borderline significant for 
major depression (p=0.063; OR=2.94; 95% CI: 
0.94-9.13) after adjusting for the same variables 
(table 5).
Stratifying by age group, in those under 37 years, 
the S allele showed a significant association with 
major depression after adjusting for comorbid 
anxiety disorders (p=0.026; OR=10.79; 95% CI: 
1.32-80.36).
Discussion
The socio-demographic characteristics of the 
participants in this study were similar to those 
reported in other parts of the world (31). Major 
depressive disorder is more frequent in women, the 
unemployed, and single or separated individuals, 
irrespective of socio-economic status. Likewise, 
the frequency of use of psychoactive substances 
did not differ greatly from that found previously 
in the national population, except for a higher 
frequency of smoking in the major depressive 
disorder cases in this study (2).
Our results showed a distribution of the 5-HTT 
gene polymorphism similar to that of three other 
Table 2. Clinical and familial variables, 5-HTT polymorphism and major depressive disorder. Paired case-control study. Bogotá, 
Colombia, 2013
Variable MDD Cases Controls p value OR (95% CI )
 
n % n %
PSC consumption   3   4.4   0 0  NA  
Lifetime smoking 19 27.9 10 14.7   0.046   2.29   (2.29-5.56)
Current alcohol consumption 17 25.0 25 36.8   0.103      0.50   (0.214-1.168)
Psychiatric hospitalization 11 16.2   0 0  NA  
Previous antidepressant treatment 32 47.1   1   1.5 <0.001  
More than one antidepressant treatment 13 19.1   0 0  NA  
MDD in family 26 38.2   3   4.4 <0.001   12.50   (2.961-52.774)
BPD in family   3   4.4   4   5.9   0.500   0.750 (0.168-3.351)
Suicide in family   5   7.4   0 0  NA  
Schizophrenia in family   4   5.9   3   4.4   0.500   1.33   (0.298-5.958)
PSC: Psychoactive substance consumption; BPD: Bipolar disorder; MDD: Major depression disorder; NA: Does not apply
Table 3. Psychiatric diagnosis and comorbidity, 5-HTT polymorphism and major depressive disorder (MDD). Paired case-control 
study. Bogotá, Colombia, 2013
 
 
 
 
MDD cases Controls p OR 
(95% CI)
n % n % 
Lifetime anxiety disorder + 21 30.9 2 2.9 <0.001   20.0   (2.684-149.028)
Agoraphobia +   7 10.3 0 0 NA  
Social phobia +   5   7.4 4 5.9   0.500 1.25 (0.336-4.655)
Obssessive-compulsive disorder +   4   5.9 3 4,4   0.500 1.33 (0.298-5.958)
Anorexia +   2   2.9 0 0 NA  
Bulimia +   3   4.4 2 2.9   0.500 1.50 (0.251-8.977)
Generalized anxiety disorder +   9 13.2 1 1.5   0.011   9.00 (1.140-71.040)
NA: Does not apply
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studies carried out in Colombian population (28-
30). The genotype frequencies of Colombian cases 
and controls including those from the present study 
are summarized in table 6.
In both Colombian studies on borderline personality 
disorder 1 (BPD1) cases, a greater frequency of 
the SS genotype and S allele was found in the 
evaluated population, similar to what was found 
in a Spanish population compared with European 
populations. The study by Ospina-Duque, et al., 
found an excess of the S allele, 53% in controls 
from Antioquia. Although Ospina-Duque did not find 
an association of 5-HTT polymorphism with BPD 1, 
they did find a greater frequency of some clinical 
characteristics of BPD 1 in the presence of the S 
allele: Greater clinical severity, greater frequency 
of manic episodes, younger age at onset of the 
disorder, and psychotic symptoms. The psychotic 
symptoms associated with the S allele reached 
statistical significance when the Ospina-Duque 
group combined them with data reported by Ho, 
et al., thereby confirming the hypothesis that the 
S allele acts as a modifier of the BPD 1 phenotype 
(28,32).
On the other hand, the BPD1 cases evaluated by 
Rengifo in the Colombian coffee growing region 
showed a non-statistically significant increase of 
the LL genotype in cases compared to controls 
(22.6% vs. 13.3%). When separated by sex, the 
LL genotype was more frequent in women with 
BPD 1 than in control women (22.7% vs. 11.6%), 
although the frequency of this genotype was similar 
in women and men with BPD 1 (22.7 % vs. 22.2%). 
The distribution of the SS genotype was similar in 
cases of BPD 1 and controls in Rengifo’s study 
(33.1% vs. 31.7%), and similar to the distribution 
found in cases of MDD and controls in our study 
(26.5% vs. 26.5%) (29).
The distribution of 5-HTT genotypes in Escobar, et 
al.´s major depressive disorder study in a population 
from Caldas department in Colombia, was similar 
to that in our study (30). Regarding the risk of major 
depression, Escobar’s study showed a tendency 
to major depression risk in the presence of the S 
allele, and, therefore, protection in its absence, 
although according to our findings, this tendency 
did not reach statistical significance (30).
We found a high comorbidity of major depression 
and anxiety disorders, particularly anxiety disorders 
at least once in participants’ lifetime. The literature 
Table 4. 5-HTT polymorphism and major depressive disorder. Genotype and allele frequency by age group. Paired case-control 
study. Bogotá, Colombia, 2013
Age (years) 5-HTT
polymorphism
Cases Controls p OR (95% CI)
All ages Genotype n % n %
LL 19 28 25 36.8  1.000
SS 18 27 18 26.5 0.514 1.38 (0.524-3.629)
SL 31 46 25 36.8 0.237 1.62 (0.729-3.596)
Alleles
S 49 72 43 63.2 0.173 1.54 (0.724-3.299)
L 19 28 25 36.8  1.000
≤36 Genotype  
LL   9 26 16 48.5  1.000
SS 10 29   9 27.3 0.299 2.32 (0.475-1.306)
SL 16 46   8 24.2 0.079 2.83 (0.887-9.011)
≥37 Alleles
S 26 74 17 51.5 0.038 2.75 (0.876-8.637)
L   9 26 16 48.5
LL 10 30   9 25.7  1.000 
SS   8 24   9 25.7 0.731 0.79 (0.203-3.061)
SL 15 46 17 48.6 0.838 0.87 (0.237-3.219)
S 23 70 26 74.3 0.500 0.83 (0.254-2.730)
L 10 30   9 25.7
Table 5. Multivariate analysis of association of the 5-HTT 
polymorphism and major depression disorder. Paired case-
control study. Bogotá, Colombia, 2013 
Variable p OR   OR 95 % CI 
Generalized anxiety disorder 0.110   6.38 0.656 - 62.132
Lifetime anxiety disorder 0.003 23.80  2.849 -198.763
SS genotype 0.288   2.14 0.527 - 8.672
SL genotype 0.049   3.20 1.003 - 10.238 
LL genotype 1.000
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has shown an association between anxiety disor-
ders and the S allele and SS genotype of the 5-HTT 
gene. As expected, major depression was also 
found to be strongly associated with suicide risk, 
and suicide risk with anxiety disorders, and this 
association persisted in the multivariate analysis, 
from which suicide risk had to be excluded due to its 
high colinearity with anxiety disorders. This strong 
association between the 5-HTT S allele, anxiety 
disorders, major depressive disorder and the risk of 
suicide was found especially in individuals under 37 
years with SS homozygotes or SL heterozygotes, 
similar to the findings of other authors (33). The 
literature also shows high rates of comorbidity 
between major depressive disorder and anxiety 
disorders. Some authors recognize anxiety as 
an axial symptom in major depression, and have 
found evidence of the relationship between the 
polymorphism evaluated in this study and anxious 
symptoms, the activity of the amygdala and 
the anxiety response (33-36). In addition, some 
authors have pointed out that the comorbid anxiety 
disorders of major depression increase implicit 
suicide risk (37).
Regarding the controversial results reported in the 
literature on the association of the 5-HTT gene in/
del polymorphism and major depression, it may 
be that sample size in some of the non-conclusive 
studies was very small and, thus, hindered their 
statistical power for finding significant differences 
between patients and controls, or they may have 
been affected by the selection of cases with very 
heterogeneous psychiatric phenotypes, a lack of 
adequate classification of cases and controls, the 
age of the compared groups, or the geographic 
origin, among other reasons (20,21). With the 
increased number of studies of this polymorphism 
and the subsequent increase in sample size, a 
greater statistical significance has been registered 
for this association, especially in the meta-analyses 
that have been undertaken.
In this study’s sample, the most frequent genotype 
was the SL heterozygote, which agrees with pre-
vious findings in the Colombian population. 
The SL heterozygote polymorphism of the 5-HTT 
gene was found to be significantly associated with 
major depression, after adjusting for comorbid 
generalized anxiety disorders and anxiety disorder 
at least once in their lifetime. The severity of suicide 
risk was found to be very significantly associated 
with major depression, and was ultimately excluded 
from the multivariate model due to its high colinearity 
with generalized anxiety disorder. The S allele of 
the 5-HTT gene, adjusting for the same variables, 
was borderline significant.
After adjusting for co-morbid anxiety disorders, 
a statistically significant association was found 
between the S allele of the 5-HTT gene and 
major depressive disorder in individuals under 
the age of 37. It is likely that younger cases of 
major depressive disorder have a higher genetic 
influence that has made them more susceptible 
to the earliest form of the disorder; therefore, it is 
more likely to find these genetic associations in 
younger people. 
Table 6. 5-HTT gene polymorphism frequency in Colombian populations
 (28) 
n (%)
(29)
 n (%)
 BPD
103 (47.9)
Controls 
112 (52.1)
Total 
(n=215)
BPD I 
133 (52.6)
Controls 
120 (47.4)
Total 
(n=253)
SS 27 (26.2) 29 (25.8) 56 (26) 44 (33.1) 38 (31.7)   82 (32.1)
LS 47 (46.5) 61 (54.4)  108 (50.2) 59 (44.4) 66 (55) 125 (49.4)
LL 29 (28.1) 22 (19.6)    51 (23.7) 30 (22.6) 16 (13.3)   46 (18.1)
 (30) 
n (%)
This article
n (%)
 MDD 59 (50) Controls 
59 (50) 
Total (n=118) MDD 
68 (50)
Controls 68 
(50)
Total (n=136)
SS 18 (30.5) 11 (18.7) 29 (24.6) 18 (26.5) 18 (26.5) 36 (26.5)
LS 27 (45.8) 30 (50.8) 57 (48.3) 31 (45.6) 25 (36.8) 56 (41.2)
LL 14 (23.7) 18 (30.5) 32 (27.1) 19 (27.9) 25 (36.8) 44 (32.4)
BPD: Bipolar disorder cases; BPD 1: Bipolar disorder 1 cases; MDD: Major depression disorder cases
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The factors associated with major depressive 
disorder were comorbidity with anxiety disorders 
(anxiety disorder at least once in their lifetime, and 
generalized anxiety disorder), suicide risk, and 
family history of depression. A familial tendency 
towards suicide was also found among cases.
This study evaluated the association between a 
single genetic polymorphism (5-HTT gene) and 
major depressive disorder. Given the polygenic 
nature of the major depressive disorder, new 
studies will be needed to evaluate multiple genetic 
characteristics.
Some associations showed a tendency towards a 
difference between the case and control groups, 
but the small sample size could have impeded a 
statistical significance level. The evaluated sample 
is not representative of the major depressive 
disorder cases in the city of Bogotá, nor do the 
controls represent the Bogotá’s local population, 
and, therefore, results cannot be generalized. The 
sample was selected from the same population 
base and was homogeneous in terms of residence 
in Bogotá. Additionally, comparability between 
cases and controls and the validity of the statistical 
analysis is supported by the fact that no statistically 
significant differences between cases and controls 
were found in socio-demographic characteristics 
such as age, gender, education, socioeconomic 
level and marital status. It would be inferred that 
cases and controls differ as regards the presence 
or absence of the major depressive disorder and 
the factors closely related to the disorder.
It is also necessary to evaluate the triallelic model of 
the 5-HTT gene and the influence of polymorphisms 
of other genes involved in the susceptibility to 
major depressive disorder. Financial limitations 
prevented further assessment of other variants in 
5-HTT gene, as well as the study of a larger sample 
of cases and controls. Subsequent studies are 
needed with larger samples that are representative 
of people with major depression in Bogotá and 
other regions of the country.
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